1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. News
  7. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gan & Lee Pharmaceuticals : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions

07/02/2021 | 03:01am EDT

BEIJING and BRIDGEWATER, NJ., July 2, 2021 /CNW/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th. The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).

All three phase 1 studies met their primary PK and primary PD analyses. These data demonstrate pharmacokinetic and pharmacodynamic bioequivalence between each of the proposed biosimilar Gan & Lee insulins and their respective reference compounds. In addition, the safety profiles were comparable between each of the three proposed biosimilar Gan & Lee insulins and their respective reference compounds1,2,3.  

The data presented from the abstracts, are a major milestone in the biosimilar clinical development programs at Gan & Lee. Although 2021 marks the centenary of insulin's discovery, insulin access remains a global health issue. "We are excited as we move one step closer to bringing biosimilar insulins into clinical practice with a goal of helping reduce the global burden of diabetes," said Jia Lu, Executive Director of Clinical Sciences. The three abstracts have recently been published on the journal Diabetes® website and the poster presentation numbers for the GL-ASP, GL-LIS, and GL-GLA abstracts are 738-P, 736-P, and 740-P, respectively.

About Gan & Lee

Gan & Lee has successfully developed the first domestic biosynthetic human insulin in China. Currently, the company has five recombinant insulin analogs and other products commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin®), fast-acting aspart injection (Rapilin™), mixed protamine zinc lispro injection (25R) (Prandilin®25) and aspart 30 injection (Rapilin™30), reusable insulin injection pen (GanleePen™), and disposable pen needle (Ganlee Fine™).

Moving forward, Gan & Lee strives to advance its goal of becoming a world-class pharmaceutical company by providing a comprehensive coverage in the field of diabetes diagnosis and treatment, and also taking an active part in developing new chemical entities for the treatment of cardiovascular diseases, metabolic diseases, cancer, and other diseases. For more information, please contact us at investorrelations@ganlee.us.

References:

1.  Leona Plum- Mörschel, et. al. Proposed biosimilar insulin aspart (GL-ASP) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin aspart. June 22, 2021.

2.  Eric Zijlstra, et. al. Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin lispro. June 22, 2021.

3.  Tim Heise, et. al. Proposed biosimilar insulin glargine (GL-GLA) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin glargine. June 22, 2021.

Gina Antonucci,
888-288-5395
investorrelations@ganlee.us

Cision
View original content:https://www.prnewswire.com/news-releases/new-data-on-phase-1-proposed-biosimilar-gan--lee-insulins-aspart-gl-asp-lispro-gl-lis-and-glargine-gl-gla-presented-at-the-american-diabetes-associations-81st-scientific-sessions-301324495.html

SOURCE Gan & Lee Pharmaceuticals Co., Ltd.

© Canada Newswire, source Canada Newswire English

All news about GAN & LEE PHARMACEUTICALS.
04/27Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 3..
CI
03/10Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug,..
AQ
03/10Gan & Lee Pharmaceuticals. Begins First-In-Human Trial in U.S. for Investigational Drug..
CI
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New..
CI
2021China’s Drug Procurement Program Cuts Insulin Costs by Around 48%
MT
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September..
CI
2021GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
More news
Financials
Sales 2022 4 002 M 597 M 597 M
Net income 2022 1 533 M 229 M 229 M
Net Debt 2022 - - -
P/E ratio 2022 15,1x
Yield 2022 -
Capitalization 23 175 M 3 459 M 3 459 M
Capi. / Sales 2022 5,79x
Capi. / Sales 2023 4,78x
Nbr of Employees 3 278
Free-Float 20,5%
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 41,27
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-41.33%3 459
CSL LIMITED-7.17%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-45.27%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229